UBS analyst Danielle Antalffy initiated coverage of DexCom with a Buy rating and $142 price target as part of a sector note on U.S. Medical Supplies and Devices. The firm believes DexCom can drive sustainable 20%+ sales growth, ahead of consensus by ~0.5% and 1% in 2023/2024, as it is in a share gain position in the Type 2 patient population with the ongoing G7 launch, and believes CGM adoption broadly in the Type 2 basal patient population will ramp quickly, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
- DexCom initiated with a Buy at UBS
- DexCom Q1 report can be a catalyst for shares, says Jefferies
- DexCom announces expanded coverage for G6 CGM System in Manitoba
- DexCom has no material exposure to developments at Silicon Valley Bank
- DexCom pullback on Abbott news a buying opportunity, says Jefferies
